Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Hempdocon Aug 29, 2020 8:55pm
162 Views
Post# 31476061

RE:RE:RE:RE:RE:RE:RE:Where did the money go?

RE:RE:RE:RE:RE:RE:RE:Where did the money go?
NeilPaert74 wrote:
Hempdoc wrote:
Hempdoc wrote:
NeilPaert74 wrote:
goldn1 wrote:
i am surprised they haven't burned thru more. We all knew they would have to do another raise at some point, hopefully they will hav covid and phase 2 results by the end of the year so it will b @ a much higher price w more institutional investors. If they don't produce anything positive by nov/dec, I think we will see a lot of ppl dumping, including myself as they can't wait until they are out of money until a raise, so I would target jan/feb...



Goldie I agree, I actually think they need to give us some details on what the Covid 19 might give them in grant money $$ at the AGM. I'm assuming 1433, what they have discovered about it, will give them excellent Covid 19 results at the U of M. Dr. Coombs should be able to get grant money for it. At the least TLT won't be spending money there next year. And yes SP should be much higher. Remember though we are still on the Vulture. I'd really like to see TLT make a move to Toronto xchange, at the least! 

So yeah by Jan/Feb like you said I'm expecting a very nice belated Christmas present from TLT. :-)
 



Hi Neil...Dr. Coombs (his specialty is in virology...good for us) has received multiple grants in the past 5 yrs & has recently received a generous grant towards the fight against Covid-19 from CIHR (Canadian Institutes of Health Research). Between this & what TLT provided (my guess 500K to 1M), we should be good to go through next year w/o the need for further funding by TLT as you said.  These collaborations TLT is forming (U of M, RP...& which will likely expand) will not only prove our technology/worth, their research will hopefully open the floodgates for more grants/public funding...taking some pressure off TLT's & softening any blow to TLT's coffers in the future when needed.  Good luck...
 

 

KEVIN COOMBS (MEDICAL MICROBIOLOGY & INFECTIOUS DISEASES/CHILDREN’S HOSPITAL RESEARCH INSTITUTE OF MANITOBA), CIHR AWARDED $790,162

 

All strategies of rapidly developing tools to mitigate this catastrophic SARS-CoV-2 pandemic are fundamentally dependent on identifying and controlling those proteins that execute the cellular mechanisms critical for the virus to infect and replicate in host cells. Coombs will lead a multi-institutional consortium using a powerful novel tool, called SOMAscan, and next-generation sequencing, to rapidly determine how COVID-19 (SARS-CoV-2 coronavirus) – and a variety of other coronaviruses – affect large numbers of genes and proteins in different human lung cells, the normal target of the COVID-19 virus.

 


 

 

https://winnipeg.ctvnews.ca/manitoba-researchers-given-millions-for-covid-19-research-1.5000960



Yep Doc,

I feel we are in good hands with RP and Dr. Sherri and Dr. Coombs. That they could do enough to get TLT grant money, move share price. I worry that current management wont do enough to get us off this Vulture xchange, where we will continue to bounce on the floor, due to manipulation...

That does weigh on my sanity. Whats left of it.



Yah...the TSX would be a start, but not certain we even have the minimum cash flow to qualify?
But very excited about RP,  Dr. Coombs & Dr. Sherri.  These partnerships will give us a much needed boost & potentially save us a boatload in $$/dilution down the road.  

Re: Dr. Commbs, my guess is he will be testing (if he hasn't already) TLD-1633 & possibly other organometallic formulations against the pertinent viruses/coronaviruses.  I hope we see TLD-1633 finally in action (both here & eventually at RP).  I'm not at all concerned about our PDCs' efficacy...they work. The key will be finding the best way to deliver & activate the PDC, including investigating the most practical/effective way to deliver our drug in both the late stages of illness (inpatients) & early stages (outpatient setting)....for the latter, perhaps via an inhaler with or w/o external activation...though drug activation by a simple outpatient head/neck/chest x-ray would be ideal.  

 

<< Previous
Bullboard Posts
Next >>